Larotrectinib manufacturer

Larotinib was developed by the American biotechnology companyLoxo Oncology. Loxo Oncology is committed to developing targeted cancer treatments, and larotrectinib is one of the company's innovations. Loxo OncologyIn its early days, it focused on biological and medical research in the field of cancer, and was later acquired by global pharmaceutical company Eli Lilly and Company (Eli Lilly). Eli Lilly and Company is a US-based international pharmaceutical company that has expanded its research and development and product portfolio in the field of cancer treatment through the acquisition of Loxo Oncology. Therefore, larotrectinib can be regarded as the research and development result of the American company Loxo Oncology and an important product of Eli Lilly and Company in the field of cancer treatment.